† A Randomized Study to Compare LDL-C-Lowering Effects of Inclisiran with Usual Care vs Usual Care Alone in Patients with Recent Hospitalization for an Acute Coronary Syndrome: Rationale and Design of the VICTORION-INCEPTION trial
Patients are at high risk for a recurrent cardiovascular (CV) event in the first year following acute coronary syndrome (ACS). Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for recurrent CV events. Despite the availability of lipid-lowering therapies (LLT), many patients fail to achieve guideline-recommended LDL-C (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Jeffrey L Anderson, Ann Marie Navar, Neerja Balachander, Nihar R Desai, Kirk U Knowlton Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research
Long-Term Efficacy and Safety of Twice-Yearly Inclisiran in Patients with ASCVD and Elevated LDL-C: A Post-Hoc Analysis of ORION-3, a 4-year Open-Label Extension Study
ORION-3 (NCT03060577) was a long-term (4-year) open-label extension to the Phase 2, double-blind, 360-day, placebo-controlled ORION-1 study. ORION-3 assessed the long-term efficacy and safety of twice-yearly inclisiran in 382 patients with atherosclerotic cardiovascular disease (ASCVD) or risk-equivalents and elevated low-density lipoprotein cholesterol (LDL-C), despite maximally tolerated statin therapy or other oral lipid-lowering therapy (LLT). Results from a post-hoc, exploratory, subgroup analysis in patients with established ASCVD are presented here. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Scott R. Wright, Kausik K Ray, Roland PT Troquay, Frank LJ Visseren, Ulf Landmesser, Wolfgang Koenig, Frederick J Raal, Lawrence A Leiter, Kelly Kleeman, Jackie Han, Gregory G. Schwartz Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research
Characteristics of Patients Initiating Inclisiran in the Real World: A Retrospective Analysis of a US Database
Inclisiran was approved by the U.S. Food and Drug Administration (FDA) in December 2021 as an adjunct to diet and maximally tolerated statin for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). It is a first in class small interfering RNA administered subcutaneously twice yearly. Studies assessing the real-world use of inclisiran in the United States (US) are scant. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Xiaoli Niu, Akhil Parlapalli, Xinshuo Ma, Jina Park, Sean McElligott, Abena Osei-Wusu Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research
† Pharmacokinetics of Mibavademab in Healthy Participants: Results from a Randomized, Phase 1, Two-Part, First-in-Human Study
Leptin is a circulating adipose-derived hormone that controls energy expenditure and glucose/lipid metabolism by binding to leptin receptors (LEPRs); leptin is critical for body weight homeostasis and is a target for replacement therapy in treating obesity due to leptin deficiency. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Jeanne Mendell, Andrew Gewitz, Yuhuan Wang, Lutz Harnisch, Benjamin A Olenchock, Hao Pan, Simona Podgrabinska, Wenjun Zheng, An Zhao, Fr édéric Vanhoutte, John D Davis Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research
† Prevalence and Clinical Outcomes of Lipodystrophy: Cross-Sectional Analyses of a US National Cohort
Limited information is available on the population-based prevalence and clinical characteristics of lipodystrophy (LD). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Seonkyeong Yang, Caitlin Knox Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research
Statins and the Risk of Breast, Lung, Colorectal, and Prostate Cancers
Apart from their lipid-lowering effects and cardiovascular (CV) benefits, the cancer protective properties of statins have attracted much attention in recent years. However, there has been inconsistent evidence on the anti-cancer effectiveness of statins, with few studies even reporting paradoxically increased cancer incidence in statin users. Due to the well-established CV benefits of statin therapy in a large proportion of adults, both in primary and secondary CV prevention, any such potential harm on cancer incidence carries significant implications. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Mounica Vorla, Pawan Daga, Muhammad Umer, Mathew Shotwell, Dinesh K Kalra Tags: Other Source Type: research
† Triglyceride Patterns among Patients in US Clinical Practice
Evidence on temporal patterns of triglyceride (TG) testing and results among US patients with severe hypertriglyceridemia (sHTG, defined as TG>=500 mg/dL) is sparse. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Emily Kutrieb, Montserrat Vera-Llonch, Asia Sikora Kessler, Jonathan L Respress, Seth J Baum, Daniel Soffer, Derek Weycker, Ellen Dukes, Hongsheng Wu Tags: Patient Management Source Type: research
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI
Patients with a recent myocardial infarction (MI) are classified as very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events according to current guidelines, however, targeted LDL-C achievement and optimizations of lipid-lowering therapy in these patients remains suboptimal. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Neha Agarwal, Shpetim Karandrea, Amanda Jamrogiewicz Tags: Other Source Type: research
Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients At High Cardiovascular Risk: CLEAR OUTCOME
Statins have been proven to lower cardiovascular events. However, some patients report adverse events from statins, most commonly muscle-related symptoms, and cannot take statins. Alternative therapies are needed to lower LDL-C in patients unable to meet guideline treatment goals. Bempedoic acid is an ATP citrate lyase inhibitor that targets cholesterol synthesis upstream of HMG-CoA reductase, the enzyme targeted by statins. It has been approved as a treatment for LDL-C lowering since 2020 based on studies that have shown LDL-C reduction of 15-25%. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Leslie Cho Tags: Pathophysiology of Atherosclerosis Source Type: research
Plasma lipoprotein subclass variation in middle-aged and older adults: sex-stratified distributions and associations with health status and cardiometabolic risk factors.
Routine clinical assessment of plasma lipids comprises total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations, as markers for atherosclerotic cardiovascular disease (ASCVD) risk1,2. Remnant cholesterol, the cholesterol content of triglyceride-rich very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL) and chylomicrons, is present in the circulation in the fasting state, with modest postprandial increases and wide inter-individual variability3. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - June 30, 2023 Category: Lipidology Authors: Reika Masuda, Julien Wist, Samantha Lodge, Torben Kimhofer, Michael Hunter, Jennie Hui, John P. Beilby, John R. Burnett, Girish Dwivedi, Markus P. Schlaich, Sze-How Bong, Ruey Leng Loo, Elaine Holmes, Jeremy K. Nicholson, Bu B. Yeap Tags: Original Research Source Type: research
Clinical Trials to Improve Outcomes in Patients with Elevated Lp(a) Undergoing PCI: The Time Has Arrived
Lipoprotein(a) [Lp(a)] is a highly prevalent, genetic, and independent risk factor for cardiovascular disease (CVD) and aortic stenosis. The underlying mechanisms of increased risk include pro-inflammatory effects of its associated oxidized phospholipids (OxPL), pro-atherogenic effects of the LDL-like moiety and antifibrinolytic effects of the inactive protease-like domain on Kringle V of apolipoprotein(a).1 Although elevated Lp(a) is associated with increased risk of CVD in both primary and secondary prevention settings, an understudied area of Lp(a) biology is its role in outcomes following percutaneous coronary interven...
Source: Journal of Clinical Lipidology - June 30, 2023 Category: Lipidology Authors: Sotirios Tsimikas, Harpreet S. Bhatia, David Erlinge Tags: Editorial Source Type: research
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands
Familial hypercholesterolemia (FH) is characterized by highly elevated plasma low-density lipoprotein cholesterol (LDL-C), a family history of hypercholesterolemia and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD)1. The main genetic causes of FH include loss-of-function mutations in the LDL receptor (LDLR) or apolipoprotein B (APOB) gene and gain-of-function mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene1. However, in approximately 20-40% percent of subjects with definite FH according to clinical diagnostic criteria, no established causal monogenic mutation can b...
Source: Journal of Clinical Lipidology - June 25, 2023 Category: Lipidology Authors: Sanna á Borg, Albert Marni Joensen, Michael René Skjelbo Nielsen, Ása Wraae Olsen, Ihab Bishara Yousef Lolas, Henrik Okkels, Søren Lundbye-Christensen, Erik Berg Schmidt, Christian Sørensen Bork Tags: Original Research Source Type: research
Lipoprotein(a) and Coronary Artery Calcium in Comparison with other Lipid Biomarkers: the Multi-Ethnic Study of Atherosclerosis
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL)-like particle composed of apolipoprotein B-100 (apoB) linked by a disulfide bond to apolipoprotein(a) (apo(a)).1 Elevated Lp(a) levels are associated with an increased risk for several cardiovascular diseases.2 Traditional risk scoring methods do not account for Lp(a),3 however, and coronary artery calcium (CAC) scoring is often used clinically to clarify risk in individuals with elevated Lp(a).4 (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - June 16, 2023 Category: Lipidology Authors: Candace L. Jackson, Parveen K. Garg, Weihua Guan, Michael Y. Tsai, Michael H. Criqui, Sotirios Tsimikas, Harpreet S. Bhatia Tags: Original Research Source Type: research
Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation
High lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease (ASCVD).1-3 Lp(a) has pro-inflammatory and pro-thrombotic properties, both of which may contribute to an increased ASCVD risk.4-7 Prior studies suggest that high Lp(a) may be associated with an increased risk for ASCVD events in adults with high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L, a marker of inflammation, but not among those with hs-CRP (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - June 10, 2023 Category: Lipidology Authors: Lisandro D. Colantonio, Sascha N. Goonewardena, Zhixin Wang, Elizabeth A. Jackson, Michael E. Farkouh, Mei Li, Waqas Malick, Shia T. Kent, J. Antonio G. L ópez, Paul Muntner, Vera Bittner, Robert S. Rosenson Tags: Original Research Source Type: research
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Multiple lines of evidence demonstrate that elevated levels of atherogenic lipoproteins are a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and their reduction is a cornerstone of ASCVD prevention.1-4 A log-linear relationship between absolute low-density lipoprotein cholesterol (LDL-C) and ASCVD risk is supported by genomic and cohort studies, and randomized clinical trials.1 A meta-analysis of 21 clinical trials of LDL-C –lowering drugs indicated that each 1-mmol/L LDL-C lowering was associated with a relative reduction in risk of major vascular events of 23% after 5 years, with increasing benefi...
Source: Journal of Clinical Lipidology - June 3, 2023 Category: Lipidology Authors: Christie M. Ballantyne, Marc Ditmarsch, John JP Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle L. Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls Tags: Original Research Source Type: research
